Spotlight Cinema Networks LLC
Total Consideration
$8.2M
Purchase-Price Allocation
Goodwill
$500.0K
Assets Acquired
$12.1M
Liabilities Assumed
$3.9M
Contingent Earn-Out
$1.3M
Pro-Forma Combined Entity
Revenue
$253.5M
Net Income
−$11.3M
16 years of history · ending 2026-01-01 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2026 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 35.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | — | — | — | — | 0.40% | 3.70% |
| Foreign Rate Differential | — | — | — | — | — | — |
| Other Adjustments | — | — | — | — | 0.40% | -1.30% |
| Valuation Allowance Change | — | — | 90.00% | 90.00% | 8.10% | 2.48% |
| Effective Tax Rate | — | — | — | — | 0.80% | 0.00% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2026 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $162.2M | — | — | — | $200.0K | — |
| Income Taxes Paid (Cash) | $500.0K | −$100.0K | $100.0K | — | $78.4K | $13.0K |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Total Consideration
$8.2M
Purchase-Price Allocation
Goodwill
$500.0K
Assets Acquired
$12.1M
Liabilities Assumed
$3.9M
Contingent Earn-Out
$1.3M
Pro-Forma Combined Entity
Revenue
$253.5M
Net Income
−$11.3M
Purchase-Price Allocation
Assets Acquired
$574.7M
Liabilities Assumed
$91.3M
Pro-Forma Combined Entity
Revenue
$259.8M
Net Income
−$200.5M
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).